MedTrace Logo

Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

NCT01102660 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2014-08-22

No results posted yet for this study

Summary

PH-797804 is a potent inhibitor of inflammatory mediators that have a potential role in pain signalling following nerve injury and inflammation. Blocking such mediators may potentially have a therapeutic benefit by reducing pain.

Conditions

Interventions

DRUG

PH-797804

Tablet, 6 mg once daily for 2 weeks

DRUG

Placebo

Tablet, 0 mg once daily for 2 weeks

DRUG

Placebo

Tablet, 0 mg once daily for 2 weeks

DRUG

PH-797804

Tablet, 6 mg once daily for 2 weeks

DRUG

Naproxen

Tablet, 500 mg twice daily for 2 weeks

DRUG

Naproxen + PH-797804

Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks

DRUG

Naproxen + PH-797804

Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks

DRUG

Naproxen

Tablet, 500 mg twice daily for 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-02-28
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01102660 on ClinicalTrials.gov